International Journal of Surgical Oncology / 2012 / Article / Tab 2

Clinical Study

Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial

Table 2

Response to neoadjuvant imatinib (NAI).

PatientTumour siteLargest tumour diameter Before NAI (cm)Largest tumour diameter After NAI (cm)Change in tumour size
(%)
Duration of NAI (months) and final dosage of imatinib (mg)RECIST response

1Rectum 2.52.2−12.012 (600)SDi
2Stomach8.35.9−28.912 (600)PRii
3Stomach41.5−62.56 (400)PR
4Duodenum136.4−50.812 (400)PR
5Stomach16.57−57.612 (400)PR
6Stomach8.73.5−59.812 (400)PR
7Stomach17.320.216.812 (600)SD
8Stomach9.1109.92 (600)SD
9Liver1.71.3−23.54 (600)SD
10Oesophagus9.25.6−39.112 (400)PR
11Duodenum2.82.3−17.912 (400)SD
12Stomach4.33.2−25.612 (600)SD
13Stomach293417.22.4 (600)SD
14Stomach5.64.5−19.66 (400)SD

Miii9.47.7−25.29SD

iSD: stable disease (less than 30% reduction or 20% increase in largest diameter).
iiPR: partial response (30% reduction or more in largest diameter).
iiiM: mean.